A mixed mode affinity chromatography carrier includes a substrate, a hydrophilic polymer, an antibody-binding cyclic peptide, and a cation exchange group.

A mixed mode affinity chromatography carrier includes a substrate, a hydrophilic polymer, an antibody-binding cyclic peptide, and a cation exchange group.

The present invention provides peptides of general formula (I) and salts thereof, wherein: R.sub.1 and R.sub.2, taken together, form a birradical linker; and R.sub.2′ is hydrogen; or, alternatively, R.sub.1 is selected from hydrogen, —C(═O)—CH.sub.2—NH—C(═O)—(C.sub.1-C.sub.5)alkyl, and —C(═O)—(C.sub.1-C.sub.20)alkyl; one of R.sub.2 and R.sub.2′ is hydrogen and the other is selected from —C(═O)NR.sub.3R.sub.4, and —C(═O)OH; and R.sub.3 and R.sub.4 are same or different and are selected from hydrogen and (C.sub.1-C.sub.10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both. ##STR00001##

The present invention provides peptides of general formula (I) and salts thereof, wherein: R.sub.1 and R.sub.2, taken together, form a birradical linker; and R.sub.2′ is hydrogen; or, alternatively, R.sub.1 is selected from hydrogen, —C(═O)—CH.sub.2—NH—C(═O)—(C.sub.1-C.sub.5)alkyl, and —C(═O)—(C.sub.1-C.sub.20)alkyl; one of R.sub.2 and R.sub.2′ is hydrogen and the other is selected from —C(═O)NR.sub.3R.sub.4, and —C(═O)OH; and R.sub.3 and R.sub.4 are same or different and are selected from hydrogen and (C.sub.1-C.sub.10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both. ##STR00001##

Polypeptides derived from fibronectin are presented that are neutrophil elastase-resistant and can bind to growth factors and/or enhance growth factor activity. These polypeptides are useful for enhancing wound healing in a patient.

Disclosed herein are compositions and methods suitable for treating acute leukemia by inhibiting π π π stacking in the YEATS protein domain. YEATS protein domains are typically found in a variety of chromatin modification molecular complexes. Cancer cells are characterized by aberrant epigenetic landscapes and often exploit chromatin machinery to activate oncogenic gene expression programs. Quantitative analysis of the inhibitory activity of YEATS domain inhibitors by use of a fluorescence-based assay revealed that several of the tested inhibitors achieved 50% inhibition at the submicro/nanomolar level. As such, provided is the use of small molecule inhibitors that target the ENL YEATS domain to selectively kill leukemic MLL-r cells.

Disclosed herein are compositions and methods suitable for treating acute leukemia by inhibiting π π π stacking in the YEATS protein domain. YEATS protein domains are typically found in a variety of chromatin modification molecular complexes. Cancer cells are characterized by aberrant epigenetic landscapes and often exploit chromatin machinery to activate oncogenic gene expression programs. Quantitative analysis of the inhibitory activity of YEATS domain inhibitors by use of a fluorescence-based assay revealed that several of the tested inhibitors achieved 50% inhibition at the submicro/nanomolar level. As such, provided is the use of small molecule inhibitors that target the ENL YEATS domain to selectively kill leukemic MLL-r cells.

The present invention provides compounds of formula (I) ##STR00001## wherein X, L.sup.1 and R.sup.1 to R.sup.10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the α3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.